New trial data showed CagriSema led to 'superior' weight loss, but at a rate less than expectations Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy ...

GDANSK/LONDON (Reuters) - Bank of America analysts on Friday said Novo Nordisk (NYSE:NVO) may miss first-quarter expectations, as sales of its blockbuster Wegovy and Ozempic drugs lag, which could ...

An Eli Lilly exec said the company’s experimental weight-loss pill ... for its potential Ozempic successor, but for the second time, it fell short of analysts’ expectations, disappointing ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial ... the company's other drugs, Ozempic, which is approved ...

Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy, the diabetes and obesity ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like Ozempic and ... those expectations may be unrealistic.

Previously, fans had urged the chart star to ... quick to question her fast weight loss. Many were convinced that the singer was using the Type 2 diabetes drug Ozempic to slim down, claims ...

Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as ...